Industry

LAVAL, Quebec–(BUSINESS WIRE)–BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications, today announced that three abstracts reviewing clinical data from the Phase 2b SOOTHE trial will be presented at the upcoming European Respiratory Society … [Read more…]

– Highly-accurate, tissue-based, next-generation sequencing (NGS) test approved in China as a companion diagnostic for targeted colon cancer therapies NATICK, Mass.–(BUSINESS WIRE)–Pillar Biosciences, the leader in Decision Medicine™, developers and distributors of next-generation sequencing (NGS) tests which localize testing and reduce time to treatment initiation and overall testing costs, today announced that its oncoRevealTM Dx … [Read more…]

Omnipod 5 is the first tubeless AID System cleared in the U.S. for preschool children ACTON, Mass.–(BUSINESS WIRE)–Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it has received clearance from the U.S. Food and Drug Administration (FDA) for its … [Read more…]

The Carl F. Braun Trust awards Children’s Hospital Los Angeles $1.92 million to conduct research on integrative techniques to alleviate pain in children. LOS ANGELES–(BUSINESS WIRE)–Children’s Hospital Los Angeles has received a gift of $1.92 million from the Carl F. Braun Trust to support a three-year research study to measure the impact of using integrative … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Otoscopes – Global Market Trajectory & Analytics” report has been added to ResearchAndMarkets.com’s offering. Global Otoscopes Market to Reach $198.1 Million by 2026 The global market for Otoscopes estimated at US$172.8 Million in the year 2022, is projected to reach a revised size of US$198.1 Million by 2026, growing at a CAGR of … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Radiopharmaceuticals – Global Market Trajectory & Analytics” report has been added to ResearchAndMarkets.com’s offering. Global Radiopharmaceuticals Market to Reach US$8.9 Billion by the Year 2026 Growth in the global market is supported by growing number of nuclear procedures driven by rise in prevalence of cancer, and heart diseases. Significant therapeutic usage of radiopharmaceuticals … [Read more…]

In-house Microbiology laboratory commissioned to accelerate product range development and enhance differentiation Experienced microbiologists will ensure drug substance quality control, perform analytics research on potential drugs, and advance new applications for proprietary form of hypochlorous acid Introduction of the new team underscores SpectrumX’s commitment to strict analytical and quality control methods, which will allow the … [Read more…]

Initiative to develop, manufacture, and validate publicly available somatic reference samples and create public genomic datasets with the potential to be used by sponsors and regulators ARLINGTON, Va.–(BUSINESS WIRE)–#MDIC–The Medical Device Innovation Consortium (MDIC) formally launched its Somatic Reference Samples (SRS) Initiative with a pilot project to improve the validation and regulatory review process for … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Molecular Diagnostics Market Size, Share, Trends, By Product & Services, By Technology, By Application, By End-use and By Region Forecast to 2030” report has been added to ResearchAndMarkets.com’s offering. The global molecular diagnostics market size is expected to reach USD 50.94 Billion in 2030 and register a revenue CAGR of 12.4% over the … [Read more…]

Rezafungin is a next-generation, once-weekly echinocandin being developed for both the treatment and prevention of serious fungal infections, such as invasive candidiasis and candidemia The European Medicines Agency (EMA) filing is supported by the pivotal ReSTORE Phase III clinical trial results, where rezafungin demonstrated non-inferiority to the current standard of care, caspofungin in the treatment … [Read more…]